Rivaroxaban
Ampulla Of Vater Cancer
Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Asan Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03139487CT.gov A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ampulla Of Vater Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivaroxaban (this asset) | Asan Medical Center | P2 | CCC · 53 |
| Dalteparin | Asan Medical Center | P2 | CCC |
| Apixaban | Asan Medical Center | P2 | CCC |
| Adh-1 Trifluroacetate | University of Nebraska | P1 | CC |
| Cis-Diamminedichloroplatinum Ii | University of Nebraska | P1 | CC |
| Irinotecan | University of Chicago | P1 | CC |
| Fluorouracilum | University of Chicago | P1 | CC |
Other indications for Rivaroxaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atrial Fibrillation | — | P4 | BBB · 79 |
| Hemorrhagic Disease | — | P4 | BBB · 76 |
| Thrombotic Disease | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivaroxaban in Ampulla Of Vater Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivaroxaban-ampulla-of-vater-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →